Amgen Advances Xaluritamig Trial in Hard-to-Treat Prostate Cancer

Amgen Inc (AMGN) announced an update on their ongoing clinical study.

Amgen is running a new early-stage trial called “A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer.” The main goal is to understand the safety of xaluritamig in people whose prostate cancer keeps growing despite hormone therapy, a group with few strong options.

The treatment being tested is xaluritamig, also known as AMG 509, given as a short intravenous infusion. It is an experimental drug designed to target advanced prostate cancer cells and offer another line of therapy for patients who have already gone through standard care.

This is an interventional study with a single treatment arm, so every enrolled patient receives xaluritamig under the same planned regimen. The study is open label, meaning both doctors and patients know they are getting the drug, and the main purpose is treatment, not prevention or diagnosis.

The trial is currently recruiting after first being submitted on March 20, 2026, which signals that study sites are now opening to enroll patients. The latest update on May 19, 2026, suggests Amgen recently refreshed the protocol or status, and final completion dates will guide when more robust safety and early activity data may reach investors.

For investors, this update underscores Amgen’s push deeper into oncology and late-stage prostate cancer, an area where new drugs can earn premium pricing if they show benefit. Progress in this Phase 1b trial, even on safety and early response signals, could lift sentiment on AMGN by reinforcing its pipeline value, while also pressuring competitors investing in next-generation prostate cancer therapies.

The study remains active and updated, and more detailed trial information is available on the ClinicalTrials.gov portal under its registered identifier.

To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.